Male breast cancer with mandibular metastasis. A case report.
Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes. Influencing factors are: gynecomasty, familiarity for male breast cancer, Jewish and African-American male population. From the histological point of view, it is not different from the female breast cancer, except for the infiltrant ductal carcinoma, but with a much severe prognosis. Breast cancer metastases to the jaws are rare, only 1%; the most common sites of metastases are: lungs(59-69%), liver (58-65%), bone (44-71%), pleura (23-37%), brain (9-22%) and kidney (4-17%). At present, based on a literature research (May 2006), there have been just two other case reports of male breast cancer metastasis to the maxillofacial region, both to the mandible. The case of a 69-year-old white man who in 2001 underwent a radical mastectomy due to ductal breast cancer is reported. In 2005 the patient was referred to our department by his oncologist for multiple oral fistula. A mandibular TC revealed osteolytic lesions and the patient underwent mandibular surgery to remove the lesions and clean up the area. The histological examination was consistent with that of a metastatic deposit of adenocarcinoma of the breast. In June 2006 the patient died due to worsening of the general clinical conditions, in particular due to ascites and hepatic insufficiency.
Fontana
S
S
Unit of Maxillofacial Surgery, Ospedali Riuniti, Bergamo, Italy. stefanosilvano.fontana@tin.it
Ghilardi
R
R
Barbaglio
A
A
Amaddeo
P
P
Faldi
F
F
Pericotti
S
S
D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D003348:Cortisone / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D017809:Fatal Outcome; D005472:Fluorouracil / Q000008:administration & dosage; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008339:Mandibular Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D015411:Mastectomy, Modified Radical; D008727:Methotrexate / Q000008:administration & dosage; D009853:Omeprazole / Q000008:administration & dosage; D010014:Osteolysis / Q000188:drug therapy / Q000209:etiology; D010634:Phenobarbital / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D017312:Toremifene / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine; D000077211:Zoledronic Acid
D000730:Androstadienes; D000964:Antimetabolites, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D000077211:Zoledronic Acid; D005665:Furosemide; D017312:Toremifene; D003520:Cyclophosphamide; D009853:Omeprazole; C056516:exemestane; D000077235:Vinorelbine; D005472:Fluorouracil; D003348:Cortisone; D008727:Methotrexate; D010634:Phenobarbital